Literature DB >> 20100879

Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.

Paul G Higgins1, Will Stubbings, Hilmar Wisplinghoff, Harald Seifert.   

Abstract

This study compared the activity of finafloxacin, a novel fluoroquinolone which shows enhanced activity under acidic pH, and that of ciprofloxacin against Acinetobacter baumannii under standard conditions (pH 7.2) and at a pH of 5.8. Overall, finafloxacin demonstrated superior activity to ciprofloxacin under acidic conditions. Furthermore, finafloxacin showed comparable activity to ciprofloxacin at pH 7.2. Hence, finafloxacin could be a promising new antimicrobial agent for the treatment of A. baumannii infections at acidic body compartments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100879      PMCID: PMC2849356          DOI: 10.1128/AAC.01637-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii.

Authors:  J Vila; J Ruiz; P Goñi; T Jimenez de Anta
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii.

Authors:  Hilmar Wisplinghoff; Mathias Decker; Christiane Haefs; Oleg Krut; Georg Plum; Harald Seifert
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

3.  Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro.

Authors:  P G Higgins; K Coleman; S G Amyes
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

4.  Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance.

Authors:  K Sato; T Nakae
Journal:  J Antimicrob Chemother       Date:  1991-07       Impact factor: 5.790

Review 5.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.

Authors:  James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Ian R Friedland; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  J Antimicrob Chemother       Date:  2004-09-08       Impact factor: 5.790

8.  Fluoroquinolone resistance of Serratia marcescens: sucrose, salicylate, temperature, and pH induction of phenotypic resistance.

Authors:  Sanela Begic; Elizabeth A Worobec
Journal:  Can J Microbiol       Date:  2007-11       Impact factor: 2.419

9.  Conditions affecting the results of susceptibility testing for the quinolone compounds.

Authors:  S M Smith; R H Eng; C E Cherubin
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

10.  Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; J Ruiz; P Goñi; A Marcos; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  15 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.

Authors:  Will Stubbings; Pamela Leow; Goh Chee Yong; Falicia Goh; Barbara Körber-Irrgang; Michael Kresken; Rainer Endermann; Harald Labischinski
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 6.  Finafloxacin: first global approval.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

7.  High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.

Authors:  Jung Won Lee; Nayoung Kim; Ryoung Hee Nam; Jung Mogg Kim; Jong Youn Park; Sun Min Lee; Joo Sung Kim; Dong Ho Lee; Hyun Chae Jung
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

8.  Effects of Saline, an Ambient Acidic Environment, and Sodium Salicylate on OXA-Mediated Carbapenem Resistance in Acinetobacter baumannii.

Authors:  Esther Zander; Harald Seifert; Paul G Higgins
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 9.  Antibiotics and bacterial resistance in the 21st century.

Authors:  Richard J Fair; Yitzhak Tor
Journal:  Perspect Medicin Chem       Date:  2014-08-28

10.  Newer antibacterials in therapy and clinical trials.

Authors:  Simi S Paknikar; Sarala Narayana
Journal:  N Am J Med Sci       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.